Common virus may kill prostate cancer cells
July 8th 2005A common virus known as adeno-associated virus type 2 (AAV2) appears to kill multiple types of cancer cells, including prostate cancer cells, in laboratory cultures yet has no effect on healthy cells, suggesting its potential to be developed as an anti-cancer agent, according to researchers from Penn State College of Medicine, Hershey, PA.
Study: No specific PSA cutoff yields high sensitivity, specificity
July 8th 2005A new study appearing in JAMA (2005; 294:66-70) suggests there is no specific PSA value that has both high sensitivity and specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate cancer risk at all values of PSA.
Protein marker is tumor specific for clear-cell RCC
July 1st 2005Anaheim, CA--Laboratory data from German investigators point to the use of the CD70 protein as a biomarker for clear-cell renal cell carcinoma and suggest that the marker could be useful in differential diagnosis in cases of uncertain histologic classification. This, in turn, could be very important clinically if found to be present in serum or urine.
Statins may reduce risk of advanced PCa by 50%
July 1st 2005Anaheim, CA--Data from a very large, prospective cohort study suggest that men taking statin drugs may reduce their risk of advanced prostate cancer by more than half and reduce their risk of metastatic or fatal disease by more than two-thirds.
Adjuvant RT shows benefit in pT3 PCa
July 1st 2005Orlando, FL--Adjuvant radiotherapy for pT3 prostate cancer significantly reduces the risk of biochemical progression after radical prostatectomy with a very low rate of side effects, according to a study by German researchers. But a U.S. radiation oncologist said the findings of this and two related studies are not powerful enough to change the current standard of care.
Seeds, conformal proton beam treatment show similar results
July 1st 2005Orlando, FL--In men with early-stage prostate cancer, permanent prostate seed implantation (PPI) appears to be as effective as high-dose conformal proton beam radiotherapy (CPBRT) in terms of biochemical control and reduction of PSA levels, according to findings from a new study.
Older, sicker men receive ADT for localized prostate Ca
July 1st 2005Orlando, FL--Men with localized prostate cancer who are treated with primary androgen deprivation therapy tend to be older and to have more comorbidities and lower incomes than men treated by other primary therapies, according to a study presented at the 2005 American Society of Clinical Oncology meeting.
Tool helps predict survival in untreated PCa patients
July 1st 2005Orlando, FL--American and British scientists have developed a statistical tool for predicting whether a man will survive his prostate cancer for up to 120 months if it is not treated immediately. Michael W. Kattan, PhD, of The Cleveland Clinic Foundation, said the tool should be helpful in patient counseling and clinical trial design.
PSA data support drop in PCa-specific mortality
July 1st 2005Orlando, FL--The PSA era has been marked by a well-known stage migration toward less aggressive and potentially more curable prostate cancer. Research now shows that, during the recent PSA era, PSA doubling times have lengthened and PSA failure rates have dropped. The findings suggest that prostate cancer-specific mortality will continue to decline, according to researchers from Tufts University and the Dana-Farber Cancer Institute, Boston.
ADT-chemo combo cuts time to progression in PCa
July 1st 2005Orlando, FL--Recent preclinical evidence now suggests that administering androgen deprivation therapy (ADT) concurrently with paclitaxel (Taxol) is more effective than sequential treatment in androgen-dependent prostate cancer. In a study presented at the 2005 American Society of Clinical Oncology annual meeting, both time to tumor progression and time to sacrifice were significantly improved in mice treated with the combination therapy compared with sequential therapy.
Hypogonadism more likely in men with diabetes
June 17th 2005Men age 45 years and older with diabetes may be more than twice as likely as non-diabetic men to have low testosterone levels, and sexual dysfunction is the most common symptom experienced by men with diabetes and hypogonadism, according to a subset analysis of the Hypogonadism in Males study.
Agent for BPH may help improve biopsy accuracy
June 17th 2005Dutasteride (Avodart) appears to improve the accuracy of prostate biopsies by suppressing blood flow in benign tissue, allowing radiologists to better target cancer tissue using Doppler ultrasound-guided biopsy, according to a small pilot study.
Botulinum toxin reduces incontinence in neurogenic OAB patients, European data show
June 2nd 2005Botulinum toxin type A (Botox) produces a rapid and sustained reduction in the number of daily incontinence episodes and markedly improves patients' quality of life, according to a European phase II clinical trial presented at the AUA annual meeting.
Mayo Clinic site explains treatment options to BPH patients
June 2nd 2005A new Health Decision Guide for men with BPH is now available on the Mayo Clinic's web site, MayoClinic.com. The guide explains treatment options, including emerging and alternative treatments, to men diagnosed with the condition.